NuPathe completes $15 million series A financing round

By Lisa Kerner

Charlotte, N.C., Sept. 13 - NuPathe Inc. completed a $15 million round of series A private equity financing to support the company's clinical programs for therapeutic products to treat migraine and other central nervous system disorders.

Birchmere Ventures and BioAdvance Ventures co-led the financing round with participation from Safeguard Scientifics, Inc. and other institutional investors, according to a company news release.

NuPathe is a specialty pharmaceutical company based in Conshohocken, Pa.

Issuer:	NuPathe Inc.
Issue:	Series A private equity financing
Amount:	$15 million
Investors:	Birchmere Ventures and BioAdvance Ventures (co-leads), Safeguard Scientifics, Inc., other institutional investors
Announcement date:	Sept. 13

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.